FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 328:453-459 February 18, 1993 Number 7 Next

	Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Although methods of viral attenuation in plasma-derived clotting-factor concentrates have improved, there is still a possibility that such concentrates may transmit certain blood-borne viruses. For this reason, the use of recombinant DNA-derived factor VIII (which is virus-free) to treat hemophilia A has generated considerable interest.

Methods We conducted a multicenter trial in previously untreated children with hemophilia A. They received recombinant factor VIII for all treatment or for prophylaxis and were evaluated at their respective clinics at intervals of no more than three months.

Results Between January 1, 1989, and July 1, 1992, 95 patients who could be evaluated received recombinant factor VIII. By September 1, 1992, they had received the concentrate exclusively for 2.4 months to 3.5 years (median, 1.5 years). All responded well, with no treatment failures. A total of 3315 infusions were administered; there were three reports of minor adverse reactions. Inhibitor antibodies to factor VIII developed in 16 of 81 patients tested for them, after a median of nine days of exposure to factor VIII treatment. Inhibitor titers were or became low in 9 of the 16 patients despite continued episodic treatment with the concentrate. Inhibitors disappeared completely in 4 patients and remained at a low level (<10 Bethesda units) in 5 patients receiving episodic treatment.

Conclusions Transient or low levels of inhibitor, as observed in this study, may represent part of the natural history of hemophilia in infants. In view of the transient nature and lower concentration of the inhibitors detected and the generally satisfactory response to treatment, the benefits of recombinant factor VIII for the treatment of hemophilia seem to outweigh the risks.

Source Information

From Children's Hospital of Michigan, Detroit (J.M.L.); Mount Sinai Medical School, New York (S.A.); the University of California, Davis (C.F.A.); and the Department of Clinical Research, Miles Inc., Berkeley, Calif. (R.S.S.). Presented in part as an abstract at the 33rd Annual Meeting of the American Society of Hematology, Denver, December 7-10, 1991.The members of the Kogenate Previously Untreated Patient Study Group are listed in the Appendix.

Address reprint requests to Dr. Lusher at Children's Hospital of Michigan, 3901 Beaubien Blvd., Detroit, MI 48201.

Full Text of this Article

This article has been cited by other articles:

• Meeks, S. L., Healey, J. F., Parker, E. T., Barrow, R. T., Lollar, P. (2008). Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors. Blood 112: 1151-1153 [Abstract] [Full Text]  
• Meeks, S. L., Healey, J. F., Parker, E. T., Barrow, R. T., Lollar, P. (2007). Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. Blood 110: 4234-4242 [Abstract] [Full Text]  
• Gouw, S. C., van der Bom, J. G., Auerswald, G., Ettinghausen, C. E., Tedgard, U., van den Berg, H. M., for the CANAL Study group, (2007). Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 109: 4693-4697 [Abstract] [Full Text]  
• Goudemand, J., Rothschild, C., Demiguel, V., Vinciguerrat, C., Lambert, T., Chambost, H., Borel-Derlon, A., Claeyssens, S., Laurian, Y., Calvez, T., the members of the FVIII-LFB and Recombinant FVIII, (2006). Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 107: 46-51 [Abstract] [Full Text]  
• Sabatino, D. E., Armstrong, E., Edmonson, S., Liu, Y.-L., Pleimes, M., Schuettrumpf, J., Fitzgerald, J., Herzog, R. W., Arruda, V. R., High, K. A. (2004). Novel hemophilia B mouse models exhibiting a range of mutations in the Factor IX gene. Blood 104: 2767-2774 [Abstract] [Full Text]  
• Parker, E. T., Healey, J. F., Barrow, R. T., Craddock, H. N., Lollar, P. (2004). Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope. Blood 104: 704-710 [Abstract] [Full Text]  
• Fischer, K.-G., Deschler, B., Lubbert, M., Wiestner, A., Weksler, B. B., Schechter, G. P. (2003). Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses. Blood 101: 3753-3754 [Full Text]  
• Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., Couto, L. B., Leonard, D. G. B., Johnson, F. A., McClelland, A., Scallan, C., Skarsgard, E., Flake, A. W., Kay, M. A., High, K. A., Glader, B. (2003). AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101: 2963-2972 [Abstract] [Full Text]  
• Desnick, R. J., Brady, R., Barranger, J., Collins, A. J., Germain, D. P., Goldman, M., Grabowski, G., Packman, S., Wilcox, W. R. (2003). Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement Therapy. ANN INTERN MED 138: 338-346 [Abstract] [Full Text]  
• Jacquemin, M., Vantomme, V., Buhot, C., Lavend'homme, R., Burny, W., Demotte, N., Chaux, P., Peerlinck, K., Vermylen, J., Maillere, B., van der Bruggen, P., Saint-Remy, J.-M. (2003). CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood 101: 1351-1358 [Abstract] [Full Text]  
• Doering, C. B., Healey, J. F., Parker, E. T., Barrow, R. T., Lollar, P. (2002). High Level Expression of Recombinant Porcine Coagulation Factor VIII. J. Biol. Chem. 277: 38345-38349 [Abstract] [Full Text]  
• Villard, S., Piquer, D., Raut, S., Leonetti, J.-P., Saint-Remy, J.-M., Granier, C. (2002). Low Molecular Weight Peptides Restore the Procoagulant Activity of Factor VIII in the Presence of the Potent Inhibitor Antibody ESH8. J. Biol. Chem. 277: 27232-27239 [Abstract] [Full Text]  
• Mannucci, P. M. (2002). Ham-Wasserman Lecture : Hemophilia and Related Bleeding Disorders: A Story of Dismay and Success. ASH Education Book 2002: 1-9 [Abstract] [Full Text]  
• Eng, C. M., Guffon, N., Wilcox, W. R., Germain, D. P., Lee, P., Waldek, S., Caplan, L., Linthorst, G. E., Desnick, R. J., the International Collaborative Fabry Disease Stud, (2001). Safety and Efficacy of Recombinant Human {alpha}-Galactosidase A Replacement Therapy in Fabry's Disease. NEJM 345: 9-16 [Abstract] [Full Text]  
• Mannucci, P. M., Tuddenham, E. G.D. (2001). The Hemophilias -- From Royal Genes to Gene Therapy. NEJM 344: 1773-1779 [Full Text]  
• Arruda, V. R., Hagstrom, J. N., Deitch, J., Heiman-Patterson, T., Camire, R. M., Chu, K., Fields, P. A., Herzog, R. W., Couto, L. B., Larson, P. J., High, K. A. (2001). Posttranslational modifications of recombinant myotube-synthesized human factor IX. Blood 97: 130-138 [Abstract] [Full Text]  
• Moreau, A., Lacroix-Desmazes, S., Stieltjes, N., Saenko, E., Kaveri, S. V., D'Oiron, R., Sultan, Y., Scandella, D., Kazatchkine, M. D. (2000). Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG. Blood 95: 3435-3441 [Abstract] [Full Text]  
• Hedner, U., Ginsburg, D., Lusher, J. M., High, K. A. (2000). Congenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia. ASH Education Book 2000: 241-265 [Abstract] [Full Text]  
• Jacquemin, M., Benhida, A., Peerlinck, K., Desqueper, B., Vander Elst, L., Lavend'homme, R., d'Oiron, R., Schwaab, R., Bakkus, M., Thielemans, K., Gilles, J.-G., Vermylen, J., Saint-Remy, J.-M. (2000). A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood 95: 156-163 [Abstract] [Full Text]  
• Fijnvandraat, K., Celie, P. H.N., Turenhout, E. A.M., ten Cate, J. W., van Mourik, J. A., Mertens, K., Peters, M., Voorberg, J. (1998). A Human Alloantibody Interferes With Binding of Factor IXa to the Factor VIII Light Chain. Blood 91: 2347-2352 [Abstract] [Full Text]  
• Fijnvandraat, K., Turenhout, E. A.M., van den Brink, E. N., ten Cate, J. W., van Mourik, J. A., Peters, M., Voorberg, J. (1997). The Missense Mutation Arg593 right-arrow Cys Is Related to Antibody Formation in a Patient With Mild Hemophilia A. Blood 89: 4371-4377 [Abstract] [Full Text]  
• Prescott, R., Nakai, H., Saenko, E. L., Scharrer, I., Nilsson, I. M., Humphries, J. E., Hurst, D., Bray, G., Scandella, D., the Recombinate and Kogenate Study Groups, (1997). The Inhibitor Antibody Response Is More Complex in Hemophilia A Patients Than in Most Nonhemophiliacs With Factor VIII Autoantibodies. Blood 89: 3663-3671 [Abstract] [Full Text]  
• Tuddenham, E G D, Laffan, M (1995). Purified factor VIII. BMJ 311: 465-466 [Full Text]  
• Hoyer, L. W. (1994). Hemophilia A. NEJM 330: 38-47 [Full Text]  
• (1993). RECOMBINANT FACTOR VIII APPEARS SAFE AND EFFECTIVE. JWatch General 1993: 4-4 [Full Text]